Global retinoblastoma studies: A review.
cancer
eye
global studies
multicentric
retinoblastoma
Journal
Clinical & experimental ophthalmology
ISSN: 1442-9071
Titre abrégé: Clin Exp Ophthalmol
Pays: Australia
ID NLM: 100896531
Informations de publication
Date de publication:
23 Jan 2024
23 Jan 2024
Historique:
revised:
05
01
2024
received:
17
08
2023
accepted:
05
01
2024
medline:
24
1
2024
pubmed:
24
1
2024
entrez:
24
1
2024
Statut:
aheadofprint
Résumé
In the current era of global health awareness for retinoblastoma (RB), the challenge that lies ahead of us is providing optimal care for children affected with RB in underdeveloped nations. The understanding of similarities and disparities between various nations across the world aids in achieving comparable outcomes. With dissolving geographic barriers and evolving collaboration, global collaborative studies on RB are becoming increasingly common. They provide real-world, robust evidence on several aspects of RB. This review discusses insights gained from global RB studies regarding the demographics, certain aspects of etiopathogenesis and epidemiology, international travel burden, disparities in clinical presentations based on national income levels, management protocols, pathology, treatment outcomes, and the effect of COVID-19 on RB care across the world. These insights are likely to impact individual practice as well as inform policy reforms.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hyderabad Eye Research Foundation
Organisme : The Operation Eyesight Universal Institute for Eye Cancer
Informations de copyright
© 2024 Royal Australian and New Zealand College of Ophthalmologists.
Références
Dunphy EB. The story of retinoblastoma. The XX Edward Jackson memorial lecture. Am J Ophthalmol. 1964;58:539-552.
Grossniklaus HE. Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson memorial lecture. Am J Ophthalmol. 2014;158(5):875-891.
Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. Genetics and molecular diagnostics in retinoblastoma-an update. Asia Pac J Ophthalmol (Phila). 2017;6(2):197-207.
Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1330-1338.
Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132(3):319-325.
Das MK. Multicenter studies: relevance, design and implementation. Indian Pediatr. 2022;59(7):571-579.
World Health Organization. The global initiative for childhood cancer. 2023 https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer
Augsburger JJ, Oehlschläger U, Manzitti JE. Multinational clinical and pathologic registry of retinoblastoma. Retinoblastoma international collaborative study report 2. Graefes Arch Clin Exp Ophthalmol. 1995;233(8):469-475.
Global Retinoblastoma Study Group, Fabian ID, Abdallah E, Abdullahi SU, et al. Global retinoblastoma presentation and analysis by National Income Level. JAMA Oncol. 2020;6(5):685-695.
Fabian ID, Khetan V, Stacey AW, et al. Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries. Eye (Lond). 2022;36(8):1571-1577.
Lloyd P, Westcott M, Kaliki S, et al. The role of maternal age & birth order on the development of unilateral and bilateral retinoblastoma: a multicentre study. Eye (Lond). 2023;37(5):966-970.
Randhawa JK, Kim ME, Polski A, et al. The effects of breastfeeding on retinoblastoma development: results from an international multicenter retinoblastoma survey. Cancers (Basel). 2021;13(19):4773.
Singh S, Nishath T, Fabian ID, et al. Seasonal variation in the diagnosis of retinoblastoma. Ophthalmic Epidemiol. 2022;11:1-6.
Bowman RJC, Foster A, Stacey A, et al. International travel to obtain medical treatment for primary retinoblastoma: a global cohort study. Int J Cancer. 2021;148(8):1858-1866.
Fabian ID, Stacey AW, Foster A, et al. Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries. Br J Ophthalmol. 2021;105(10):1435-1443.
Kaliki S, Ji X, Zou Y, et al. Lag time between onset of first symptom and treatment of retinoblastoma: an international collaborative study of 692 patients from 10 countries. Cancers (Basel). 2021;13(8):1956.
Global Retinoblastoma Study Group. The global retinoblastoma outcome study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 2022;10(8):e1128-e1140.
Nishath T, Li X, Chandramohan A, et al. Risk factors associated with abandonment of care in retinoblastoma: analysis of 692 patients from 10 countries. Br J Ophthalmol. 2022;107:1818-1822.
Fabian ID, Stacey AW, Bowman R, et al. Retinoblastoma management during the COVID-19 pandemic: a report by the Global Retinoblastoma Study Group including 194 centers from 94 countries. Pediatr Blood Cancer. 2021;68(1):e28584.
Tomar AS, Finger PT, Gallie B, et al. Global retinoblastoma treatment outcomes: association with national income level. Ophthalmology. 2021;128(5):740-753.
Tomar AS, Finger PT, Gallie B, et al. A multicenter, international collaborative study for American Joint Committee on Cancer staging of retinoblastoma: part II: treatment success and globe salvage. Ophthalmology. 2020;127(12):1733-1746.
Tomar AS, Finger PT, Gallie B, et al. A multicenter, international collaborative study for American Joint Committee on Cancer Staging of retinoblastoma: part I: metastasis-associated mortality. Ophthalmology. 2020;127(12):1719-1732.
Tomar AS, Finger PT, Gallie B, et al. Metastatic death based on presenting features and treatment for advanced intraocular retinoblastoma: a multicenter registry-based study. Ophthalmology. 2022;129(8):933-945.
Tomar AS, Finger PT, Gallie B, et al. Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging. Br J Ophthalmol. 2023;107(1):127-132.
Tomar AS, Finger PT, Gallie B, et al. High-risk pathologic features based on presenting findings in advanced intraocular retinoblastoma: a multicenter, international data-sharing American Joint Committee on Cancer study. Ophthalmology. 2022;129(8):923-932.
Dunkel IJ, Piao J, Chantada GL, et al. Intensive multimodality therapy for extraocular retinoblastoma: a Children's Oncology Group trial (ARET0321). J Clin Oncol. 2022;40(33):3839-3847.
Global Health Research Group on Children's Non-Communicable Diseases Collaborative. Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic. BMJ Glob Health. 2022;7(10):e008797.
Global Health Research Group on Children's Non-Communicable Diseases Collaborative. Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study. BMJ Open. 2022;12(4):e054690.
Naseripour M. Retinoblastoma survival disparity: the expanding horizon in developing countries. Saudi J Ophthalmol. 2012;26(2):157-161.
Chantada GL, Dunkel IJ, Qaddoumi I, et al. Familial retinoblastoma in developing countries. Pediatr Blood Cancer. 2009;53(3):338-342.
Mallipatna A, Marino M, Singh AD. Genetics of retinoblastoma. Asia Pac J Ophthalmol (Phila). 2016;5(4):260-32. Mills MB, Hudgins L, Balise RR, Abramson DH, Kleinerman RA. Mutation risk associated with paternal and maternal age in a cohort of retinoblastoma survivors. Hum Genet. 2012;131(7):1115-1122.
Su Q, Sun X, Zhu L, et al. Breastfeeding and the risk of childhood cancer: a systematic review and dose-response meta-analysis. BMC Med. 2021;19(1):90.
Wikén I, Andersson TM, Radkiewicz C. Seasonal effects on cancer incidence and prognosis. Acta Oncol. 2023;62(2):103-109.
Klímová B, Kuča K. Medical tourism: its research and implications for public health. Cent Eur J Public Health. 2020;28(3):226-229.
Fabian ID, Reddy A, Sagoo MS. Classification and staging of retinoblastoma. Community Eye Health. 2018;31(101):11-13.
Munier FL. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014;35(4):193-207.
Scelfo C, Francis JH, Khetan V, et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol. 2017;10(6):961-967.
Mourits DL, Hartong DT, Bosscha MI, Kloos RJ, Moll AC. Worldwide enucleation techniques and materials for treatment of retinoblastoma: an international survey. PloS One. 2015;10(3):e0121292.
Abramson DH, Shields CL, Jabbour P, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retina Vitreous. 2017;3:40.
Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 2011;129(11):1492-1494.
Francis JH, Abramson DH, Ji X, et al. Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy. JAMA Ophthalmol. 2017;135(12):1426-1429.
Abramson DH, Ji X, Francis JH, Catalanotti F, Brodie SE, Habib L. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol. 2019;103(4):488-493.
Olteanu C, Dimaras H. Enucleation refusal for retinoblastoma: a global study. Ophthalmic Genet. 2016;37(2):137-143.
Chantada GL, Doz F, Orjuela M, et al. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2008;50(3):692-694.
Kaliki S, Shields CL, Cassoux N, et al. Defining high-risk retinoblastoma: a multicenter global survey. JAMA Ophthalmol. 2022;140(1):30-36.
Kaliki S, Shields CL, Eagle RC Jr, Iram S, Shields JA. High-risk intraocular retinoblastoma: comparison between Asian Indians and Americans from two major referral centers. Retina. 2018;38(10):2023-2029.